The short answer: Predictive, generative and agentic are capabilities, not product categories, and most revenue cycle tools combine them. Predictive capability scores what is likely to happen, such as which claims will deny. Generative capability produces language, such as a draft appeal. Agentic capability plans and executes multi-step work, such as moving a denial from identification through submission. The useful question for a buyer is not which label a vendor uses. It is which actions the product takes on its own and which it leaves to a person. Advantum Health runs AI inside its own platform, operated by its own staff, because the right technology in the wrong process still produces the wrong result.
Why this matters: the category you buy determines the risk you accept
Every revenue cycle vendor now says AI. The word has stopped carrying information. What still carries information is the question of what the system does when it is uncertain, and who is responsible for the output.
That question has a different answer depending on what the product does, and the answer is the basis of the buying decision. A tool that ranks your denial queue wrongly wastes a morning. A tool that files the wrong appeal on the wrong claim creates a payer record you have to unwind. Often the same underlying technology, very different blast radius.
The three capabilities, and what each does
Predictive capability. Scores likelihood from historical patterns: denial propensity, propensity to pay, likelihood of underpayment, expected days in accounts receivable. On its own it produces a score rather than an action, though plenty of products act on the score automatically. Its failure mode is a misranked worklist, and that can go unnoticed for a long time, because nobody audits the claims that never rose to the top. Prioritizing finite staff time is a problem every practice has, which is why this capability appears in revenue cycle products earliest and most often.
Generative capability. Produces language. Appeal letters, payer correspondence, documentation summaries, coding queries, patient billing explanations. Its value is drafting speed on work that is high-volume and formulaic. Its failure mode is fluent inaccuracy, which a reviewer does not always catch quickly. Advantum’s own control is to review generative output before it reaches a payer or a patient, with the depth of review set by what the output costs if it is wrong.
Agentic capability. The term has no industry-standard definition, which is itself a reason to ask for the action list rather than the label. As used here it refers to systems designed to plan and execute a sequence of steps toward a goal, interacting with other systems along the way: pulling a remittance, checking a payer policy, assembling documentation, submitting. The value is removing handoffs rather than accelerating a single task. The failure mode compounds, because a system that makes an early wrong decision keeps going. This is where the gap between demonstration and production is widest.
Where AI in revenue cycle management stands today
Adoption data is worth reading, and worth reading carefully. The surveys below cover different respondent groups and were conducted separately. They do not add up to a single industry figure, and none of them measures return.
A 2026 survey of more than 200 revenue leaders conducted with the Healthcare Financial Management Association found that 37 percent of health systems use generative AI in the revenue cycle, rising to 48 percent among large systems, with denial-related workflows the most common application at 45 percent. Among organizations not yet using it, 85 percent reported interest.
A separate HFMA survey of healthcare finance professionals found 27 percent deploying AI at scale across multiple functions and 53 percent running pilots. On the agentic side, Deloitte’s 2026 health care outlook survey reported that more than 80 percent of executives expect agentic and generative AI to deliver moderate to significant value, and that more than 80 percent of health systems are prioritizing agentic AI for revenue cycle management among other areas.
Taken separately, each points to the same gap between intent and production use. What none of them establishes is which capability pays off, or by how much. Adoption figures tell you what peers are buying. They do not tell you what worked.
How to evaluate a revenue cycle AI claim
Four questions cut through most vendor material.
Which actions does it take on its own? Ask for the list, not the label. A product described as agentic that surfaces a ranked worklist is doing prediction with a better interface. That is not a criticism. It is a pricing and risk question, and it is the question a data sheet will not answer.
What happens when it is uncertain? Does it escalate, abstain or proceed? A system with no abstention behavior will be confidently wrong at scale.
What is the baseline? A claimed improvement is meaningless without the denominator. Denial rate against what prior period, on what payer mix, with what staffing held constant?
Who is accountable for the output? If a generated appeal misstates a clinical fact, or an agent submits to the wrong payer, whose name is on it? The answer should be a person at an organization you can call, not a model.
Where this goes wrong
Automating a broken process. An AI layer on a workflow with bad front-end data produces wrong answers faster. Fix the eligibility and registration inputs before you accelerate anything downstream.
Buying autonomy you cannot supervise. If your team cannot review what the system did, you have not bought efficiency. You have bought an unaudited process.
Handing the tool to people whose job it replaces without saying so. Adoption fails quietly when the people expected to use a system reasonably suspect what it is for. Name the intent.
Measuring activity instead of cash. Claims touched, letters generated and queue items cleared are activity metrics. Net collections, denial rate, days in accounts receivable and cost to collect are the ones that matter.
A checklist for revenue cycle leaders
- Ask every vendor to classify its product as predictive, generative or agentic, and hold them to the answer.
- Pick one workflow with a clean baseline before buying anything broader.
- Require a documented escalation path for low-confidence outputs.
- Require human review on anything that reaches a payer or a patient.
- Confirm outputs are logged, attributable and reversible.
- Define the success metric in dollars and days before go-live, not after.
- Check whether your practice management and clearinghouse contracts already include capabilities you are about to buy separately.
- Review vendor data handling against your business associate agreement obligations before the pilot, not at renewal.
Build the process, then add the technology
The revenue cycle rewards precision over speed. A faster wrong claim is still a denial, and a fluent appeal built on a documentation gap still loses. That is why the sequencing matters more than the tooling: define the workflow, establish the baseline, then apply the capability that fits the problem.
Advantum Health builds AI into its own platform, and Advantum’s own experienced revenue cycle staff operate it rather than the models being handed to clients. The technology surfaces risk and prioritizes work for people who stay accountable for the output. That structure is what makes accountability real rather than contractual.
Part two of this series looks at the harder question underneath all of this: what an AI agent should be allowed to decide without a person in the loop. In the meantime, a revenue cycle assessment can show which of your workflows would actually benefit and which need process work first.